The Japan medical devices market size was valued at USD 39.06 billion in 2024 and is projected to grow from USD 41.36 billion in 2025 to USD 64.40 billion by 2032, exhibiting a CAGR of 6.5% during the forecast period. Medical devices encompass a broad range of tools — from injection pens and ultrasound systems to pacemakers and capnography meters — used by healthcare facilities for diagnosis and treatment.
Key Market Drivers
1. High Burden of Chronic Diseases
Japan faces a rising prevalence of chronic conditions including cancer, diabetes, cardiac disorders, and Alzheimer's disease. According to the World Health Organization (WHO), approximately 1,005,157 new cancer cases were registered in Japan in 2022, with colorectal cancer accounting for 14.5% of new cases. The International Diabetes Federation reported that around 8.97 million adults — roughly 8.1% of Japan's adult population — suffered from diabetes in 2024. Additionally, data from the Alzheimer's Association (2025) indicates approximately 7.2 million people are living with Alzheimer's Disease, particularly prevalent among those aged 85 and above. Rising accidental injuries further fuel hospital admissions and demand for devices.
2. Growing Geriatric Population
Japan has one of the world's most rapidly aging populations. This demographic shift is directly increasing the demand for home-care devices, long-term monitoring equipment, and chronic disease management tools, all of which represent a growing segment of the market.
3. Favorable Government Policies
Supportive Japanese government initiatives and reimbursement reforms are facilitating new product innovations and advanced medical device launches, further enhancing market growth.
Get a Free Sample PDF - https://www.fortunebusinessinsights.com/enquiry/request-sample-pdf/japan-medical-devices-market-113929
Market Restraints
Despite strong growth drivers, the market faces notable challenges. The high cost of medical equipment — with capnometers ranging from USD 1,000 to USD 22,000, and optical coherence tomography (OCT) devices costing between USD 8,000 and USD 70,000 — limits adoption. Additionally, Japan is grappling with a shortage of skilled healthcare professionals, driven by its aging population and declining birth rates. Stringent regulatory environments also increase the timeline and cost of bringing new products to market.
Market Opportunities
A growing emphasis on clinical trials in Japan is expected to significantly boost market awareness and adoption. For example, Amgen initiated a Phase 3 clinical trial in April 2024 to study the autoinjector-administered drug Rocatinlimab for atopic dermatitis, with 7 of 47 study locations based in Japan. As more global and domestic manufacturers conduct trials locally, it is expected to accelerate product penetration throughout the forecast period.
Segmentation Analysis
By Type
The market spans a wide range of device categories including cardiovascular, orthopedic, diagnostic imaging, minimally invasive surgery (MIS), in-vitro diagnostics (IVD), wound management, diabetes care, ophthalmic, dental, nephrology, and general surgery devices.
- In-vitro Diagnostics (IVD) held the largest market share in 2024, driven by new product launches. For example, Sysmex Corporation commercialized the HISCL C-Peptide Assay Kit in March 2025 for diabetes diagnosis.
- Dental Devices are projected to grow at the fastest CAGR during the forecast period, driven by the rising burden of dental disorders and increased product launches.
By End-User
- Hospitals & ASCs dominated the market in 2024. Japan had 710 general hospital beds per 100,000 population in 2023, reflecting strong hospital infrastructure.
- Clinics are expected to grow at the fastest CAGR, supported by the rising prevalence of chronic diseases driving outpatient demand.
Competitive Landscape
Leading global players including Johnson & Johnson, Medtronic, GE Healthcare, and Stryker held significant market shares in 2024. These companies are actively investing in product launches, acquisitions, and partnerships to strengthen their positions.
Notable developments include:
- Medtronic launched the Aurora EV-ICD™ MRI device in Japan in March 2025 for ventricular arrhythmia treatment.
- Stryker acquired Artelon, Inc. in July 2024 to expand its soft tissue fixation portfolio.
- Sysmex Corporation collaborated with Nippon Life Insurance in June 2025 to develop a disease risk assessment model for chronic conditions.
- Johnson & Johnson launched the Japan Smart Healthy Aging QuickFire Challenge in October 2024, inviting global innovators to improve healthcare technology offerings.
Conclusion
Japan's medical devices market represents a robust and expanding opportunity, underpinned by an aging population, rising chronic disease burden, and strong government support. While high device costs and regulatory complexity pose challenges, increasing clinical trial activity and continuous innovation by major market players are expected to sustain strong growth through 2032.